Teva Can Launch Neupogen Biosimilar One Month Before Patent Expiration

Under a settlement with Amgen, Teva can begin selling its G-CSF product in November 2013; the launch may be sooner if a third party launches or wins an infringement suit.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet